Q3 2025 EPS Estimates for Biogen Inc. (NASDAQ:BIIB) Decreased by Zacks Research

Biogen Inc. (NASDAQ:BIIBFree Report) – Investment analysts at Zacks Research cut their Q3 2025 earnings per share (EPS) estimates for Biogen in a research note issued on Tuesday, April 2nd. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $4.88 per share for the quarter, down from their previous forecast of $5.02. The consensus estimate for Biogen’s current full-year earnings is $15.48 per share. Zacks Research also issued estimates for Biogen’s FY2025 earnings at $17.74 EPS, Q1 2026 earnings at $3.95 EPS and FY2026 earnings at $17.96 EPS.

Several other research firms have also weighed in on BIIB. Oppenheimer dropped their price target on Biogen from $295.00 to $290.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 14th. Wedbush upped their price target on Biogen from $239.00 to $245.00 and gave the company a “neutral” rating in a research report on Monday, February 12th. William Blair reaffirmed an “outperform” rating on shares of Biogen in a research report on Monday. StockNews.com lowered Biogen from a “buy” rating to a “hold” rating in a research report on Tuesday, February 20th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $340.00 target price on shares of Biogen in a research report on Monday, March 25th. Nine research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $305.68.

Read Our Latest Stock Analysis on BIIB

Biogen Trading Down 3.3 %

Shares of NASDAQ BIIB opened at $207.64 on Wednesday. The company has a market cap of $30.18 billion, a price-to-earnings ratio of 26.02, a P/E/G ratio of 1.79 and a beta of -0.02. Biogen has a 12 month low of $207.58 and a 12 month high of $319.76. The company has a quick ratio of 1.26, a current ratio of 2.00 and a debt-to-equity ratio of 0.46. The business has a fifty day simple moving average of $227.73 and a 200-day simple moving average of $241.08.

Biogen (NASDAQ:BIIBGet Free Report) last announced its earnings results on Tuesday, February 13th. The biotechnology company reported $2.95 EPS for the quarter, missing the consensus estimate of $3.18 by ($0.23). Biogen had a net margin of 11.81% and a return on equity of 14.91%. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.47 billion. During the same period in the prior year, the company earned $4.05 earnings per share.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 262 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $221.23, for a total value of $57,962.26. Following the completion of the sale, the insider now owns 4,886 shares in the company, valued at approximately $1,080,929.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Priya Singhal sold 262 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $221.23, for a total value of $57,962.26. Following the completion of the transaction, the insider now directly owns 4,886 shares of the company’s stock, valued at approximately $1,080,929.78. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Eric K. Rowinsky bought 455 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was bought at an average cost of $222.54 per share, with a total value of $101,255.70. Following the completion of the acquisition, the director now owns 20,629 shares in the company, valued at approximately $4,590,777.66. The disclosure for this purchase can be found here. In the last quarter, insiders sold 789 shares of company stock worth $182,213. 0.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Biogen

Hedge funds have recently modified their holdings of the stock. Nomura Holdings Inc. acquired a new stake in Biogen during the 4th quarter valued at $757,000. HighPoint Advisor Group LLC acquired a new stake in Biogen during the 4th quarter valued at $496,000. Livelsberger Financial Advisory acquired a new stake in Biogen during the 4th quarter valued at $26,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Biogen during the 4th quarter valued at $6,469,000. Finally, M3 Advisory Group LLC acquired a new stake in Biogen during the 4th quarter valued at $219,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Company Profile

(Get Free Report)

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

Featured Stories

Earnings History and Estimates for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.